Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aileron Therapeutics Inc.

www.aileronrx.com

Latest From Aileron Therapeutics Inc.

Finance Watch: NGM Bio Is Second NASH IPO In Two Weeks

Public Company Edition: NGM went public a week after Genfit, but endured a rockier start, trading below its IPO price. Also, Blueprint, Tricida and Sangamo launch large offerings after positive clinical and regulatory updates.

Financing Business Strategies

Venture Funding Deals: Two Companies With China Ties Raise $260m Each

Suzhou-based immuno-oncology specialist CStone raised a $260m Series B round and Brii launched with $260m in Series A cash to develop drugs for the China market. Also, multiple start-ups launched recently with more than $50m in Series A rounds, including Ansun, Beam, Casma, Celsius and Neurana.

Deals Financing

IPOs In Review: Biopharma Offerings Bounced Back In 2017 As Returns Rose

With an average return of 33.2% in 2017, the number of biopharma IPOs that launched last year rose to 42 after falling to 30 in 2016 compared with 62 in 2015. Following a rough fourth quarter for biopharma stocks, will the IPO momentum continue in 2018?

Financing Business Strategies

IPO Update: New Offerings Outperform As September Ends With Biopharma Trifecta

There have been 29 IPOs in the US through the third quarter of 2017 with an average return of 35.2%, including three offerings on the same day – Deciphera, Nightstar and NuCana – near the end of September.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Aileron Therapeutics Inc.
  • Senior Management
  • Manuel C Aivado, MD, PhD, Pres. & CEO
    Donald Dougherty, SVP, CFO
  • Contact Info
  • Aileron Therapeutics Inc.
    Phone: (617) 995-0900
    281 Albany St.
    Cambridge, MA 02139
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register